High flow nasal therapy in the management of hypoxemic dyspnea at the end of life.

Support Care Cancer

Main Regional Center for Pain Relief & Supportive/Palliative Care, La Maddalena Cancer Center, Palermo, Italy.

Published: November 2021

Refractory dyspnea is challenging for physicians treating patients near to the end of life. High-flow nasal therapy (HFNT). We report a case in which HFNS was effective in a patient in the last days of life to mitigate dyspnea allowing a minimal quality of life for some days before dying. HFNT may be helpful for severely hypoxemic patients who are unresponsive to common measured adopted in the last weeks-days of life of advanced cancer patients. Future studies should assess an early use of this device in combination with lower doses of opioids or as an alternative.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121635PMC
http://dx.doi.org/10.1007/s00520-021-06279-6DOI Listing

Publication Analysis

Top Keywords

nasal therapy
8
life
5
high flow
4
flow nasal
4
therapy management
4
management hypoxemic
4
hypoxemic dyspnea
4
dyspnea life
4
life refractory
4
refractory dyspnea
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!